Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022;22:45–64.
Google Scholar
Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, et al. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 2019;133:566–75.
Google Scholar
Chiba M, Shimono J, Ishio T, Takei N, Kasahara K, Ogasawara R, et al. Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. Blood. 2022;140:1951–63.
Google Scholar
Ishio T, Kumar S, Shimono J, Daenthanasanmak A, Dubois S, Lin Y, et al. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma. Blood. 2022;139:1541–56.
Google Scholar
Chiba M, Shimono J, Suto K, Ishio T, Endo T, Goto H, et al. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma. Blood. 2024;143:1379–90.
Google Scholar
Suto K, Takei N, Yokoyama K, Chiba M, Ishio T, Maeda M, et al. Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma. Leukemia. 2025;39:243–7.
Google Scholar
Nakagawa M, Shaffer AL 3rd, Ceribelli M, Zhang M, Wright G, et al. Targeting the HTLV-I-regulated BATF3/IRF4 transcriptional network in adult T cell leukemia/lymphoma. Cancer Cell. 2018;34:286–97.e210.
Google Scholar
Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15:554.
Google Scholar
Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393–403.
Google Scholar
Szklarczyk D, Nastou K, Koutrouli M, Kirsch R, Mehryary F, Hachilif R, et al. The STRING database in 2025: protein networks with directionality of regulation. Nucleic Acids Res. 2025;53:D730–37.
Google Scholar
DeWeirdt PC, Sangree AK, Hanna RE, Sanson KR, Hegde M, Strand C, et al. Genetic screens in isogenic mammalian cell lines without single cell cloning. Nat Commun. 2020;11:752.
Google Scholar
Kabir S, Cidado J, Andersen C, Dick C, Lin PC, Mitros T, et al. The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells. Elife. 2019;8:e44288.
Kostrhon S, Prabu JR, Baek K, Horn-Ghetko D, von Gronau S, Klugel M, et al. CUL5-ARIH2 E3-E3 ubiquitin ligase structure reveals cullin-specific NEDD8 activation. Nat Chem Biol. 2021;17:1075–83.
Google Scholar
Hundley FV, Sanvisens Delgado N, Marin HC, Carr KL, Tian R, Toczyski DP. A comprehensive phenotypic CRISPR-Cas9 screen of the ubiquitin pathway uncovers roles of ubiquitin ligases in mitosis. Mol Cell. 2021;81:1319–36.e1319.
Google Scholar
Lin S, Larrue C, Scheidegger NK, Seong BKA, Dharia NV, Kuljanin M, et al. An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML. Cancer Discov. 2022;12:432–49.
Google Scholar
Lin S, Schneider C, Su AH, Alexe G, Root DE, Stegmaier K. The UBE2J2/UBE2K-MARCH5 ubiquitination machinery regulates apoptosis in response to venetoclax in acute myeloid leukemia. Leukemia. 2024;38:652–6.
Google Scholar
Nakao F, Setoguchi K, Semba Y, Yamauchi T, Nogami J, Sasaki K, et al. Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance. Leukemia. 2023;37:1028–38.
Google Scholar
Zhang L, Fairall L, Goult BT, Calkin AC, Hong C, Millard CJ, et al. The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor. Genes Dev. 2011;25:1262–74.
Google Scholar
Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938–47.
Google Scholar
Watanabe M, Saeki Y, Takahashi H, Ohtake F, Yoshida Y, Kasuga Y, et al. A substrate-trapping strategy to find E3 ubiquitin ligase substrates identifies Parkin and TRIM28 targets. Commun Biol. 2020;3:592.
Google Scholar
Scotti E, Calamai M, Goulbourne CN, Zhang L, Hong C, Lin RR, et al. IDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor. Mol Cell Biol. 2013;33:1503–14.
Google Scholar
Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science. 2009;325:100–4.
Google Scholar
Hyer ML, Milhollen MA, Ciavarri J, Fleming P, Traore T, Sappal D, et al. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat Med. 2018;24:186–93.
Google Scholar
Song Y, Liu J, Zhao K, Gao L, Zhao J. Cholesterol-induced toxicity: an integrated view of the role of cholesterol in multiple diseases. Cell Metab. 2021;33:1911–25.
Google Scholar
Yano H, Fujiwara Y, Horlad H, Pan C, Kai K, Niino D, et al. Blocking cholesterol efflux mechanism is a potential target for antilymphoma therapy. Cancer Sci. 2022;113:2129–43.
Google Scholar
Lambert G, Charlton F, Rye KA, Piper DE. Molecular basis of PCSK9 function. Atherosclerosis. 2009;203:1–7.
Google Scholar
Szanto A, Narkar V, Shen Q, Uray IP, Davies PJ, Nagy L. Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ. 2004;11:S126–143.
Google Scholar
Lefebvre P, Benomar Y, Staels B. Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab. 2010;21:676–83.
Google Scholar
Maura F, Agnelli L, Leongamornlert D, Bolli N, Chan WC, Dodero A, et al. Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. Am J Hematol. 2019;94:628–34.
Google Scholar
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48.
Google Scholar
de Leval L, Gaulard P, Dogan A. A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas. Blood. 2024;144:1855–72.
Google Scholar
Ito Y, Shimono J, Kawamoto K, Hatanaka KC, Kogure Y, Tabata M, et al. TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma. Leukemia. 2025;39:1723–34.
Google Scholar
Lee SD, Priest C, Bjursell M, Gao J, Arneson DV, Ahn IS, et al. IDOL regulates systemic energy balance through control of neuronal VLDLR expression. Nat Metab. 2019;1:1089–100.
Google Scholar
Li J, Li Z, Li X, Li Z, Song Y, Yuan L, et al. MYLIP attenuates hypoxia tolerance by inducing K27-linked polyubiquitination and subsequent proteasomal degradation of HIF-alpha. Commun Biol. 2025;8:774.
Google Scholar
Hong C, Duit S, Jalonen P, Out R, Scheer L, Sorrentino V, et al. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J Biol Chem. 2010;285:19720–6.
Google Scholar
